



FINANCIAL TRUST COMPANY INC

For the Period 4/1/12 to 4/30/12

Note: P indicates position adjusted for Pending Trade Activity.

\*\* Unrealized Gain/Loss is shown as "N/A" in cases where we do not have appropriate cost information for all tax lots comprising the position. Please contact your J.P. Morgan team for additional information.

## Equity Detail

	Price	Quantity	Value	Adjusted Tax Cost Original Cost	Unrealized Gain/Loss	Est. Annual Inc. Accrued Div.	Yield
<b>US Large Cap Equity</b>							
<b>ARIAD PHARMACEUTICALS INC</b> 04033A-10-0 ARIA	16.30	16,535.000	269,520.50	251,475.52	18,044.98		
<b>BIOGEN IDEC INC</b> 09062X-10-3 BIIB	134.01	2,095.000	280,750.95	250,454.95	30,296.00		
<b>DB CONT BUFF EQ MS 08/07/12</b> 25% CONTIN BARRIER- 13%CPN 30% CAP INITIAL LEVEL-07/15/11 MS:21.09 2515A1-A7-6	81.37	1,000,000.000	813,700.00	1,000,000.00	(186,300.00)		
<b>HSBC MARKET PLUS SPX 05/17/13</b> 72% KO BARRIER- 0%CPN ,UNCAPPED INITIAL LEVEL-02/14/12 SPX:1350.50 4042K1-XQ-1	101.67	5,000,000.000	5,083,500.00	5,000,000.00	83,500.00		
<b>SG MARKET PLUS SPX 02/07/13</b> 75% CONTIN BARRIER- 6.25%CPN ,UNCAPPED INITIAL LEVEL-08/03/11 SPX:1,260.34 78423A-2Y-7	108.93	2,000,000.000	2,178,600.00	2,000,000.00	178,600.00		
<b>Total US Large Cap Equity</b>			<b>\$8,626,071.45</b>	<b>\$8,501,930.47</b>	<b>\$124,140.98</b>	<b>\$0.00</b>	<b>0.00%</b>

J.P.Morgan

Account [REDACTED] Page 5 of 26 Consolidated Statement Page 8